RESUMEN
BACKGROUND: Preliminary data have suggested that interleukin-2 receptor blockade with basiliximab may increase steroid sensitivity. We have previously reported a small case series demonstrating the potential of basiliximab as a novel agent for the treatment of steroid-resistant ulcerative colitis. AIM: To report further experience of the efficacy and safety of treatment with the interleukin-2 receptor blocking monoclonal antibody basiliximab, in addition to steroids, for the treatment of severe and moderate steroid-resistant ulcerative colitis. METHODS: Twenty patients were enrolled - 13 patients with moderate steroid-resistant ulcerative colitis (Ulcerative Colitis Symptom Score: >or=6) and seven patients with severe steroid-resistant ulcerative colitis. All were given a single dose of 40 mg basiliximab plus standard steroid therapy in an open-label, uncontrolled trial. Primary end point was clinical remission within 8 weeks (Ulcerative Colitis Symptom Score: Asunto(s)
Anticuerpos Monoclonales/administración & dosificación
, Colitis Ulcerosa/tratamiento farmacológico
, Inmunosupresores/administración & dosificación
, Proteínas Recombinantes de Fusión/administración & dosificación
, Adolescente
, Adulto
, Anciano
, Antiinflamatorios/administración & dosificación
, Anticuerpos Monoclonales/efectos adversos
, Basiliximab
, Colectomía
, Colitis Ulcerosa/cirugía
, Ciclosporina/administración & dosificación
, Esquema de Medicación
, Femenino
, Humanos
, Inmunosupresores/efectos adversos
, Infusiones Intravenosas
, Masculino
, Persona de Mediana Edad
, Prednisolona/administración & dosificación
, Calidad de Vida
, Receptores de Interleucina-2/antagonistas & inhibidores
, Proteínas Recombinantes de Fusión/efectos adversos
, Índice de Severidad de la Enfermedad
, Resultado del Tratamiento